VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | Efficacy of ubrogepant based on response to triptans

Andrew Blumenfeld, MD, The Neurology Center of Southern California, Carlsbad, CA, discusses a post-hoc analysis of pooled data from the pivotal trials ACHIEVE I and II (NCT02828020, NCT02867709) to determine the efficacy of ubrogepant for acute treatment of migraine based on prior exposure and response to triptans. Dr Blumenfeld highlights that the use of triptans can be limited by insufficient efficacy, poor tolerability, or contraindications. Therefore, gepants such as ubrogepant may represent an effective alternative treatment option. Results from the pooled analysis indicate that failure to respond to triptans did not predict a failure to respond to ubrogepant, suggesting that ubrogepant may be effective and well-tolerated for the acute treatment of migraine in participants with an insufficient response to triptans (due to lack of efficacy or intolerance). This interview took place during the European Academy of Neurology 2021 congress.


Dr Blumenfeld reports the following disclosures:
Advisory Board: Allergan, Abbvie, Aeon, Alder, Amgen, Axsome, Biohaven, Impel, Lundbeck, Lilly, Novartis, Revance, Teva, Theranica, Zoscano
Speaker fees: Allergan, Abbvie, Amgen, Biohaven, Lundbeck, Lilly, Teva
Consultant: Allergan, Abbvie, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, Theranica
Grant support: Allergan, Amgen
Contributing author: Allergan, Abbvie, Amgen, Novartis, Teva, Lilly, Biohaven